Evidence map›Paper›PMID 39835420›Full record

ArticleChemMedChem2025

Effects of Cholesterol on the Breast Cancer Resistance Protein: Studies through the Synthesis and Biological Evaluation of Chemical Tools.

Ingrid Fatima Zattoni, Bruna Estelita Rugisnk, Isadora da Silva Zanzarini, Alan Guilherme Gonçalves, Vivian Rotuno Moure, Glaucio Valdameri, Ahcène Boumendjel

Abstract read
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ingrid Fatima ZattoniGraduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, 80210-170, PR, Brazil.
Bruna Estelita RugisnkGraduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, 80210-170, PR, Brazil.
Isadora da Silva ZanzariniGraduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, 80210-170, PR, Brazil.
Alan Guilherme GonçalvesDepartment of Pharmacy, Federal University of Parana, Curitiba, PR, Brazil.
Vivian Rotuno MoureGraduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, 80210-170, PR, Brazil.
Glaucio ValdameriGraduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, 80210-170, PR, Brazil.
Ahcène BoumendjelUniv. Grenoble Alpes, INSERM, LRB, 38000, Grenoble, France.ORCID https://orcid.org/0000-0002-1830-6409

Funding

Brazilian Research Council 404286/2021-6CBH-EUR-GS ANR-17-EURE-0003Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) - Finance Code 001Fundação Araucária-PPSUS SUS2020131000003
6 · The paper itself

Abstract

The breast cancer resistance protein (BCRP/ABCG2) plays a major role in the multidrug resistance of cancers toward chemotherapeutic treatments. It was demonstrated that cholesterol regulates the ABCG2 activity, suggesting that lower levels of membrane cholesterol decrease the ABCG2 activity in mammalian cells. However, the precise mechanism remains unclear. To better understand the role of cholesterol in the ABCG2 activity, we studied the ABCG2-mediated efflux of different substrates in the presence of different concentrations of cholesterol. Moreover, we synthetized derivatives of cholesterol linked either to known ABCG2 inhibitors or fluorescents probes. A chalcone-cholesterol was synthetized to investigate the influence of cholesterol on ABCG2 inhibition, and a BODIPY-cholesterol was developed to track cholesterol trafficking on mammalian cells and investigate the behavior of cholesterol as an ABCG2 substrate. The obtained results with three different substrates of ABCG2 showed that cholesterol did not affect the intracellular amount of substrates nor the transport activity.

Indexed as

ATP Binding Cassette Transporter, Subfamily G, Member 2CholesterolNeoplasm ProteinsBoron CompoundsDose-Response Relationship, DrugFluorescent DyesHumansMolecular StructureStructure-Activity Relationship4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneABCG2 protein, humanATP Binding Cassette Transporter, Subfamily G, Member 2Boron CompoundsCholesterolFluorescent DyesNeoplasm ProteinsABCG2Chemical toolsChemoresistanceCholesterolCholesterol conjugates

Identifiers

PMID39835420
PMCPMC12005470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.